Call for drug price cuts no threat to ETF tracking U.S. biotech

Call for drug price cuts no threat to ETF tracking U.S. biotech


Despite a call by U.S. President Donald Trump to cut drug prices, there are no concerns about the outlook for an Exchange Traded Fund that is listed on the local main board to track the U.S. biotech index, according to market analysts. In a news conference held Jan. 11, days before Trump was sworn in, he vowed to change the way that drugs are reimbursed in the U.S. market to rein in drug prices, remarks that sent ripples through the NASDAQ Biotechnology Index , although the fundamentals of the index remained sound, the analysts added.



from Biotech News